



PHARMACEUTICAL 2019









PHARMACEUTICAL 2019



CymaBay Therapeutics Inc. Rank 61 of 363



The relative strengths and weaknesses of CymaBay Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CymaBay Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 110% points. The greatest weakness of CymaBay Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 217%, being 180% points above the market average of 37%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 181,562 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 14,415 |
| Liabilities, Non-Current | 0 |
| Other Assets | 2,280 |
| Other Compr. Net Income | -14 |
| Other Expenses | 0 |
| Other Liabilities | 1,914 |
| Other Net Income | -43 |
| Other Revenues | 0 |
| Property and Equipment | 2,905 |
| Research and Development | 58,124 |
| Selling, General and Administrative Expense | 14,381 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 186,747 |
| Liabilities | 16,329 |
| Expenses | 72,505 |
| Revenues | 0 |
| Stockholders Equity | 170,418 |
| Net Income | -72,548 |
| Comprehensive Net Income | -72,555 |
| Economic Capital Ratio | 217% |

